Health Care & Life Sciences » Biotechnology | Minerva Neurosciences Inc.

Minerva Neurosciences Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
-
33.90
17.30
16.50
11.10
17.50
Gross Income
-
33.90
17.30
16.50
11.10
17.50
SG&A Expense
3,161.00
54,836.60
26,092.30
30,174.20
41,159.10
51,712.40
EBIT
3,161.00
54,870.40
26,109.60
30,190.70
41,170.20
51,729.90
Unusual Expense
14.00
10.10
-
-
-
-
Non Operating Income/Expense
29.00
18.70
15.90
23.40
56.90
4.90
Interest Expense
59.60
2,059.80
1,053.10
1,029.70
614.30
110.40
Pretax Income
3,262.00
56,901.40
27,081.60
31,045.40
40,899.50
50,171.30
Income Tax
-
-
-
-
9,376.30
-
Consolidated Net Income
3,262.00
56,901.40
27,081.60
31,045.40
31,523.20
50,171.30
Net Income
3,262.00
56,901.40
27,081.60
31,045.40
31,523.20
50,171.30
Net Income After Extraordinaries
3,262.00
56,901.40
27,081.60
31,045.40
31,523.20
50,171.30
Net Income Available to Common
3,262.00
56,901.40
27,081.60
31,045.40
31,523.20
50,171.30
EPS (Basic)
0.00
4.47
1.16
0.99
0.83
1.29
Basic Shares Outstanding
18,439.50
12,724.40
23,412.20
31,514.20
37,937.20
38,792.60
EPS (Diluted)
0.18
4.47
1.16
0.99
0.83
1.29
Diluted Shares Outstanding
18,439.50
12,724.40
23,412.20
31,514.20
37,937.20
38,792.60
EBITDA
3,161.00
54,836.60
26,092.30
30,174.20
41,159.10
51,712.40
Non-Operating Interest Income
1.60
-
96.90
198.50
941.80
1,673.90

About Minerva Neurosciences

View Profile
Address
1601 Trapelo Road
Waltham Massachusetts 02451
United States
Employees -
Website http://www.minervaneurosciences.com
Updated 07/08/2019
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. Its product portfolio includes MIN-101, MIN-117, MIN-202 and MIN-301. The company was founded by Rogerio Vivaldi Coelho on April 23, 2007 and is headquartered in Cambridge, MA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.